.@NewtGingrich is spot on. Foreign Rx price controls & US middlemen are the problem, NOT a solution. Wealthy countries protect their own industries at expense of US patients, families & innovators as PBMs fleece them at home Read more here: gingrich360.substack.com/p/rethinking-w… Most Favored Patient

US drug manufacturers are responding to Trump's pressure to equalize drug prices at home and abroad. reuters.com/business/healt…

.Newt Gingrich hits the nail on the head in his recent article. It is true that the U.S. drug pricing system can be improved. However, “…importing European-style price controls would make the system worse. The better path is to pursue reforms that build on what already works."

Foreign price controls weaken America’s leadership in healthcare innovation. Holding freeloaders accountable strengthens an America First agenda. Say no to more price controls and yes to direct-to-patient sales. Donald J. Trump The White House @buisness bloomberg.com/news/articles/…

Well said, Newt Gingrich. Thank you for highlighting our Blueprint for American Patients. Let's bring transparency back into the healthcare market. Phil Kerpen Stephen Moore

.@RealDonaldTrump winning on Rx prices. Allowing direct-to-patient models to bypass insurers-PBMs provides 80% + price decrease. Then add $300b+ invested in US drug manufacturing/jobs since Jan. But be mindful. gov. price controls would do the opposite bloomberg.com/news/articles/…

.The White House is ending foreign free-riding on America’s medical innovation. Price controls kill progress and import socialized medicine. Donald J. Trump is holding other nations accountable, easing the burden on U.S. patients. GOP Doctors Caucus Chuck Grassley reuters.com/business/healt…

Transparency in healthcare is key to keeping costs down for Americans.

New Bloomberg article shares how DTP sales are providing huge discounts to American patients and achieving Donald J. Trump's healthcare agenda. Read more: bloomberg.com/news/articles/… Phil Kerpen Stephen Moore Steve Forbes

To lower drug costs for Americans, Donald J. Trump is holding foreign freeloaders accountable. Read more about how President Trump is driving meaningful change in the healthcare market: fiercepharma.com/pharma/lilly-c… Phil Kerpen Stephen Moore Steve Forbes FiercePharma

Foreign freeloading on America's innovation has increased drug prices and discouraged innovation. Donald J. Trump is working to eliminate barriers to affordable #Rx & safeguard domestic R&D investment. Read more: bbc.com/news/articles/… Phil Kerpen Stephen Moore Steve Forbes

"Among the most simple and transformative reforms offered by Trump is his push to allow direct-to-patient sales of medicines straight from U.S. drug manufacturers." Read more from Stephen Moore & Jim McLaughlin about the impact of DTP: washingtonexaminer.com/restoring-amer… Phil Kerpen

.Donald J. Trump was right—DTP sales are lowering #Rx costs for patients and manufacturers. We need President Trump to finish the job and cut out insurers and their middlemen. The White House Bloomberg bloomberg.com/news/articles/…

Key for direct-to-consumer drug sales (80%+ winning issue): we need regulatory changes to make cash sales count towards deductibles and out-of-pocket caps. Then you have competition between the direct channel and insurance/PBM channel with downward price pressure on both.

Price controls won't lower drug costs. Here's what will: - Sell directly to patients & cut out the middlemen - Make countries pay their fair share for brand-name drugs - Reform the FDA to bring new drugs to market faster & cheaper We need SMART reforms! mostfavoredpatient.org/resources/coal…

.Donald J. Trump is making healthcare an 80/20 issue for Republicans. He and Dr. Mehmet Oz can continue to achieve his healthcare goal of lowering drug prices by championing DTP sales. Learn more in the letter led by Stephen Moore, Steve Forbes, & Phil Kerpen: mostfavoredpatient.org/resources/mfp-…

Best HC reform approach? "Demand in ongoing trade negotiations that other rich countries commit to increasing spending on brand drugs, which will result in the development of more new cures and lower U.S. prices." Read our full letter to President Donald J. Trump & Dr. Mehmet Oz: mostfavoredpatient.org/resources/mfp-…

Big wins for @RealDonaldTrump The White House in ending foreign freeloading and securing $350b+ US manufacturing (besting China), but PBM & 340B reforms, and avoiding price controls, critical for full patient benefits. mostfavoredpatient.org/resources/coal…

.Stephen Moore is exactly right—President Donald J. Trump is driving down drug costs and ending foreign freeloading by implementing direct-to-patient sales. Thank you, President Trump, for bringing transparency and accountability back to our healthcare system.